Research

DLEUs and VLUs treated with vCPM and vLPM allografts are associated with lowered 1-year mortality, wound recurrence, and AOs in DLEUs and VLUs compared with standard care. Decision makers weighing coverage of placental allografts should consider these added short- and long-term clinical benefits relative to costly management and high mortality of Medicare’s most frequent wounds.

Research findings suggest that policies limiting hospitals’ promotion of MPPs may need to be coupled with efforts to stabilize hospital finances, as hospitals may be using MPP promotion when they lack the resources to offer long-term interest-free financing.

Hospitals designated as trauma centers charged higher prices for nontrauma inpatient admissions and nontrauma emergency department visits when compared with hospitals that were not designated as trauma centers.

Part D plans became significantly more restrictive over time, rising from an average of 31.9 percent of compounds restricted in 2011 to 44.4 percent restricted in 2020.

Subjective cognitive impairment was more prevalent than probable dementia

Individuals are risk-seeking at low levels of health and are most risk-averse at perfect health

Alternative financing mechanisms for drugs that deliver significant long-term value for patients could strike a balance between encouraging innovation and accessibility.

Generalized Risk-Adjusted Cost-Effectiveness (GRACE) offers a choice-consistent alternative that admits a premium for disease severity and avoids prohibited discrimination under well-defined conditions on utility and the effects of disability.

Provider misperceptions that patients do not want ORS play the biggest role in the underprescribing of ORS.

Aligning drug prices with the actual value provided to patients stimulates innovation that benefits patients and discourages innovation that does not.